Clinical Efficacy And Safety Of Apatinib Combined With S-1 In Advanced Esophageal Squamous Cell Carcinoma

Objective:To evaluate the clinical efficacy and safety of apatinib combined with S-1 in the treatment of advanced ESCC patients after first-line chemotherapy failure;and analysis of the possible factors affecting the therapeutic effect of the study regimen.Methods:In this prospective study,fifteen patients with advanced ESCC who failed first-line chemotherapy were enrolled from Nov 2016 to Apr 2019.Patients received the combination therapy with apatinib(250-500 mg,once daily)plus S-1(40–60 mg based on body surface area,twice daily).Primary endpoint was progression-free survival(PFS).Secondary endpoints included overall survival(OS),disease control rate(DCR)and objective response rate(ORR).Adverse events(AEs)were recorded to evaluate the safety.Results:A total of 12 patients were included in the efficacy analysis.The median PFS was 6.23 months,and the median OS was 8.83 months.Two(16.67%)patients achieved partial remission,9 patients(75.00%)achieved stable disease and 1(8.33%)patient achieved progressive disease.DCR and ORR was 91.67%and 16.67%,respectively.Most frequent AEs were hypertension(40%)and weakness(33.33%).The most AEs were in grade I～II.Conclusion:The combination therapy of apatinib plus S-1 was effective and well tolerated in the treatment of advanced ESCC patients after first-line chemotherapy failure.The combination therapy has the potential to be a potent therapeutic option for advanced ESCC patients after first-line chemotherapy failure.